Thomas Strüngmann
Thomas Strüngmann | |
|---|---|
| Born | Template:Birth year and age Germany |
| Occupation(s) | Entrepreneur, investor |
| Known for | Investments in biotechnology and pharmaceuticals; co-owner of Athos KG |
Thomas Strüngmann (born 1950) is a German entrepreneur, investor, and billionaire. Together with his identical twin brother and business associate, Andreas Strüngmann, he has generated considerable wealth predominantly through investments in biotechnology and pharmaceuticals. They oversee their family fortune, valued at approximately $30 billion, through their single family office, Athos KG, placing them among the top wealth holders in Germany.
Career
In 2004, the Strüngmann twins acquired an 89.6% ownership in Südwestbank via Santo Holding from DZ Bank. They later divested this stake to BAWAG in 2017 for an undisclosed amount.
The following year, they sold Hexal to Novartis for $6.7 billion. After this transaction, Thomas assumed a leadership role at Sandoz, a Novartis subsidiary, managing operations across Germany, the Americas, and the Middle East.
In 2008, their asset management company Athos participated by underwriting 25% of a capital increase at Conergy. That same year marked their leading role in a €136.5 million seed investment round for BioNTech within a total €150 million funding that enabled the company's inception. Their holdings in BioNTech have since appreciated significantly, generating $8 billion and constituting about half of the company's equity. Additionally, they possess substantial shares in 4SC and Immatics, ranking them as the foremost healthcare wealth accumulators.
In 2014, Santo Holding partnered with EQT AB to purchase Siemens Audiology Solutions from Siemens for €2.2 billion, prompting Siemens to cancel its planned IPO.
The brothers continue managing their ventures through their family office, Athos Service.
See also
References